---

MONOCLONAL ANTIBODY INDEX^©

Volume 1: Cancer. (14th edition, 2011)
Volume 2: Transplant, infection, heart. (12th edition, 2011)
including in both volumes the BIOMARKER INDEX^© (4th edition, 2011)

Since 1992 near the front line of Immunology.

and the VACCINE ANTIGEN INDEX^© (7th edition, 2011)
including the ONCOLYTIC VIRUS INDEX^© (5th edition, 2011)

---

The MONOCLONAL ANTIBODY INDEX^© is a fully searchable biotechnology database with yearly updated information on more than 9000 monoclonal antibodies produced for the diagnosis and therapy of human cancer, AIDS, SARS and other infections, heart, vascular and coagulation diseases, transplantation, inflammation, Alzheimer's disease, autoimmunity and other pathologies or uses as well as for biomarker and proteomics research, indicating all available data on:

- Antibody name(s) - Antibody species - Antibody type - Antibody characteristics - Related antibodies - Target tissue/cell type - Target disease or use - Antigen or biomarker name - Antigen molecular weight - Antigen characteristics - Clinical study phase - Patent assignee, producer, developer or distributor and their respective technical or commercial names for the antibody, antigen or derivatives. - References of production, characteristics and use obtained from journals, patents, abstracts, press releases and reports available until January 2011.

Information distributed between volume 1 with more than 4800 antibodies, main and related, and volume 2 with more than 4700 antibodies. Including anti-idiotypic, bispecific, human, humanized, chimeric, reshaped, deimmunized, multivalent, diabodies, single chain-Fv (scFv), minibodies, affibodies, peptabodies, fusion proteins, transgenic, Fab fragments, pseudo-antibodies, catalytic, aglycosylated, glycosylated, pegylated, immunotoxins, conjugates, trifunctional, immunoadhesins, piezoimmunosensors, mimobodies, single domain, nanobodies, vaccibodies, intrabodies, immunocytokines, triplebodies, hexavalent, aptamers, etc.

Information presented in an easy-to-screen table format with selected data on:

- Who are the leaders?: over 600 products in clinical study for imaging and therapy with 48 approvals (some withdrawed or suspended) and 70 in phase 3.

- What's up now?: new antibodies added in the latest edition .

- Which are the targets?: included in the BIOMARKER INDEX^© annex with the characteristics of the main target antigens / epitopes / gene products / biomarkers (more than 1500 in vol. 1 and more than 1000 in vol. 2).

The VACCINE ANTIGEN INDEX^© is a fully searchable database of cells, antigens, DNA plasmids, vectors, antibodies and adjuvants ranked by study phase as vaccines for cancer (589 products with 329 in clinical study, 12 approvals and 35 in phase 3) and for other main or emerging diseases (245 products with 113 in clinical study, 3 approvals and 6 in phase 3).

The ONCOLYTIC VIRUS INDEX^© contains information on specific oncolytic viruses and cytolytic cell lines (175 products with 42 in clinical study, 1 approval and 3 in phase 3)

Three all-in-one, up-to-date reference databases (no additional modules to buy) and a great brainstorming tool that will show you the latest advances, give clues on future trends and save you a lot of time (and money) in bibliographic searches on monoclonal antibodies, a technology born in 1975 with a proven therapeutic and diagnostic utility and with worldwide sales of more than $26 billion in 2007 that are expected to reach more than $49 billion by 2013. The revenues from the top five therapeutic antibodies (Rituxan, Remicade, Herceptin, Humira and Avastin) nearly doubled from $6.4 billion in 2004 to $11.7 billion in 2006.

Therapeutic vaccines reached 16 billion sales in 2007 and cancer vaccines are expected to increase sales from more than $1 billion in 2008 to 8.4 billion by 2012. The molecular diagnostics segment of the immunoassay market is expected to increase from $12 billion in 2005 to $19 billion in 2010.

The latest editions are available as software databases.

LICENSE PRICES (plus VAT if applicable, see below):

Volumes 1 and 2 of the MONOCLONAL ANTIBODY INDEX and the VACCINE ANTIGEN INDEX, with the included annexes indicated, are sold separately as licenses and according to the following prices:

New customer (first purchase) :

   "First site" license (FS): 750 $US*. Special offer, save 25% !! : volumes 1 and 2 of the MONOCLONAL ANTIBODY INDEX for 1125 $US*.
   "Additional site" license (AS): 375 $US*. Available up to 2 for each FS license purchased.
   "Local network" license (LN): not available at present time.

Annual updates (available ONLY for old customers** who have previously purchased "first site" (FS), "additional site" (AS) or "local network" (LN) licenses of any previous edition of the corresponding e-book volume:

   "First site update" (FSU) license: 375 $US*.
   "Additional site update" (ASU) license: 375 $US*.

*Payment can be made in other currencies according to the updated exchange rate indicated in http://fxtop.com, for Euroland (euros), Australia, Canada, Great Britain, Japan, Switzerland and Sweden.

** Old customers must have exactly the same purchaser's name which they had when they purchased FS licenses to be considered as such (i.e. merged companies with a new name or companies with a changed name will be considered new customers).

Value added tax: individuals of the European Union and Spanish companies or public organizations (but not other companies or public organizations of the EU with VAT code or from the rest of world) have to add 18% VAT to the indicated prices. Companies or public organizations resident in the European Union and which do not have or do not indicate their VAT code will also be charged with 18% VAT.

New editions: will be available on March/April of every year and will include all the products of previous editions, with the new data available on them, plus the new antibodies, antigens and vaccines added.

Software information, registration and license terms. Very important.

Sales: fill in this order form and follow the instructions. Gallart Biotech SL is the only worldwide legal producer and distributor of the MONOCLONAL ANTIBODY INDEX^©, VACCINE ANTIGEN INDEX^©, BIOMARKER INDEX^© and ONCOLYTIC VIRUS INDEX^©. Our sales policy is based on clear and relevant information, guaranteed purchase and privacy of customer's data.

Software delivery: by e-mail attachment .

GALLART BIOTECH SL
VATcode: ES-B60133519

LINKS:
Biomarker discovery and identification technology system.
Mutation prediction algorithm for multiresistant microorganisms.

Recycle and reduce residues using software...

Thanks for visiting and don't forget to bookmark us !! (add to "Favorites" or press Ctrl+D).